Phaseline

Companies › NoNO

NoNO: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 3; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NoNO-42–Phase 2Acute Ischemic Stroke; StrokeDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06403267NoNO-42Phase 2Acute Ischemic StrokeNeurologyDec 2026
NCT06352632NoNO-42Phase 3StrokeNeurologySep 2034

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.